Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » CDC: New Flu Vaccine Ready After Harsh 2017-2018 Season

    CDC: New Flu Vaccine Ready After Harsh 2017-2018 Season

    October 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Ready for flu season? Follow new guidelines

    Focus on Staff Immunization After Bad Flu Season

    A variety of new influenza vaccination alternatives on tap for the coming flu season

    Related Products

    Mild flu season softens impact of vaccine delay | Single Article

    Half the nation’s flu vaccine for this season is delayed | Single Article

    Does flu vaccine wane during season? | Single Article

    On the heels of a brutal 2017-2018 flu season, the vaccine strains for the 2018-2019 season have been set. The CDC recommends “routine annual influenza vaccination is for all people six months and older if they have no contraindications. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2018–19 season.”1

    Also, recommendations regarding the use of LAIV4 have been revised, putting the mist vaccine popular with children back on the table under certain restrictions.

    Citing lack of efficacy, the CDC did not recommend the live vaccine last year or the prior season. The decision to recommend the vaccine came after the CDC’s Advisory Committee on Immunization Practices (ACIP) reviewed several sources of efficacy data.

    While including the live attenuated vaccine as an option, ACIP said LAIV4 should not be administered “to children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a healthcare provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months.”

    In addition, the live vaccine is contraindicated for those who are immunocompromised for any reason. “Close contacts and caregivers of severely immunosuppressed persons who require a protected environment” should not use LAIV4, either. Nor should pregnant women or people who have received antiviral medications within the prior 48 hours, the CDC recommends.

    Vaccine Strains

    The CDC and its ACIP committee advisors determined the 2018–2019 U.S. trivalent influenza vaccines will include these strains:

    • A/Michigan/45/2015 (H1N1)pdm09–like virus
    • A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
    • B/Colorado/06/2017–like virus (Victoria lineage).1

    “Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013–like virus (Yamagata lineage),” the CDC stated.

    The overall vaccine efficacy was estimated to be only 40% in the 2017-2018 season.

    The main problem was a mismatch between the circulating influenza A (H3N2) strain and the one in the vaccine. For H3N2, the vaccine was only 25% effective, but even that low efficacy reduces the chance of a person seeking medical treatment by one-fourth.

    “The 2017-2018 influenza season was a high severity season with high levels of outpatient clinic and emergency department visits for influenza-like illness (ILI), high influenza-related rates, and elevated and geographically widespread influenza activity for an extended period,” the CDC reported.2

    Last season, flu illness ran high for a long time — from January 2018 through the end of March.

    “ILI peaked at 7.5%, the highest percentage since the 2009 flu pandemic, which peaked at 7.7%,” the CDC concluded.

    “ILI was at or above the national baseline for 19 weeks, making the 2017-2018 season one of the longest in recent years.”2

    A record number of child deaths occurred in 2017-2018, totaling 180 children. Only 20% of them had been immunized, the CDC reported.

    REFERENCES

    1. Grohskopf LA, Sokolow LZ, Broder KR, et al. CDC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season. MMWR 2018;67(3):1–20.
    2. CDC. Summary of the 2017-2018 Influenza Season. Aug. 31, 2018: https://bit.ly/2rkXwPk.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 45, No. 10) - October 2018
    October 1, 2018

    Table Of Contents

    Outcasts: HAIs Stigmatize Discharged Patients

    Staffing Woes: IP-Hospital Beds Ratio Outdated

    SHEA: Avoid Routine Testing for C. diff in the NICU

    ‘Why the Foley?’ Initiative Grabs Attention, Prevents CAUTIs

    Joint Commission Revises IC Devices Standard

    FDA Adds New Safety Warning for Fluoroquinolones

    CDC: New Flu Vaccine Ready After Harsh 2017-2018 Season

    EMTs Treating Opioid Patients Succumb to Illness

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing